Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. develops and commercializes soft-tissue reconstruction solutions for surgeons, with a focus on products designed to preserve and restore patient anatomy while limiting long-term exposure to permanent synthetic materials. Its OviTex portfolio includes configurations used in hernia repair and abdominal wall reconstruction, including ventral, inguinal and hiatal procedures.
Company news commonly covers quarterly and annual results, revenue guidance, commercial execution, product portfolio updates, credit and capital actions, board and leadership changes, and equity compensation grants made under Nasdaq inducement-grant rules.
TELA Bio, Inc. (NASDAQ: TELA) announced the approval of stock options for 13 newly-hired employees, totaling 50,950 shares. The options, with an exercise price of $9.00 per share, were granted on April 27, 2022, under Nasdaq Rule 5635(c)(4) as part of their employment compensation. The options will vest over four years, with 25% vesting after one year and the remainder in monthly installments. The company's focus is on innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving the patient's anatomy.
TELA Bio, Inc. (NASDAQ: TELA) announced it will report its first quarter 2022 financial results on May 10, 2022, at 4:30 p.m. ET. The call will provide insights into the company’s performance in soft-tissue reconstruction solutions that prioritize patient anatomy restoration. Interested parties can access the conference by dialing specific numbers for U.S./Canada and international participants, or via the company's investor website. TELA emphasizes its commitment to innovative, economically effective healthcare solutions while cautioning that forward-looking statements carry inherent risks.
TELA Bio, Inc. announced the hiring of D. Taylor Ocasio as the new General Counsel. With nearly ten years in corporate law and healthcare, Ocasio previously served as Deputy General Counsel at Zynerba Pharmaceuticals and held positions at Catalent Pharma Solutions and prominent law firms. CEO Antony Koblish expressed confidence in Ocasio's extensive knowledge in life sciences and corporate securities, highlighting his potential contributions to TELA's growth. TELA focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving the patient's anatomy.
TELA Bio, a medical technology company, announced its participation in the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12, 2022, at 2:15 PM ET. TELA Bio focuses on soft-tissue reconstruction solutions that prioritize preserving the patient's anatomy. Management will present at the conference, and interested parties can access the live and archived webcast via their investor relations website. TELA Bio is committed to providing advanced technologies that enhance clinical outcomes while reducing reliance on permanent synthetic materials.
TELA Bio, Inc. (Nasdaq: TELA) reported strong financial results for Q4 and full year 2021, with revenues of $8.4 million for Q4, up 48%, and $29.5 million for the year, reflecting a 62% growth. Gross profit for Q4 was $5.7 million (68% margin), while full-year gross profit was $18.8 million (64% margin). Operating expenses increased to $13.3 million in Q4 and $48.3 million for the year, leading to a net loss of $8.6 million in Q4 and $33.3 million annually. TELA anticipates 2022 revenue between $40 million and $45 million, indicating continued growth despite potential COVID-19 challenges.
TELA Bio, Inc. (NASDAQ: TELA) announced its participation in the Canaccord Genuity Musculoskeletal Conference to be held on March 22, 2022, in Chicago, IL. The company aims to provide innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving patients’ anatomy. Management will present at 3:30 PM CT, and a live and archived webcast will be accessible via their investor relations site. TELA Bio focuses on economically effective technologies that leverage natural healing responses while reducing reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA) announced its forthcoming financial results for Q4 and full year 2021, scheduled for release on March 21, 2022. The company specializes in innovative soft-tissue reconstruction solutions that enhance clinical outcomes. A conference call will follow at 4:30 p.m. ET the same day, allowing investors to discuss the financial results. TELA prioritizes the preservation of the patient's anatomy while minimizing reliance on permanent synthetic materials. More details can be found on TELA's investor relations website.
TELA Bio, a medical technology company, has launched the SiteGuard No Rinse Antimicrobial Solution, aimed at preventing surgical site infections in plastic reconstructive surgery. Utilizing proprietary XBIO Technology, it targets bacterial biofilms that resist standard treatments, providing over five hours of protection. Early market feedback has been positive, and TELA aims to expand awareness nationwide. The product aligns with TELA's commitment to innovative soft-tissue solutions that minimize reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA) announced on February 25, 2022, the approval of stock options for 17 newly hired employees, totaling 63,800 shares. The options have an exercise price of $11.75 per share, reflecting the closing price on the grant date. These options are part of the employment agreement and will vest over four years, with 25% vesting after the first year and the rest monthly. TELA focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes while preserving patients' anatomy.
TELA Bio reported third quarter 2021 revenue of $7.7 million, a 44% year-over-year increase. Increased demand for OviTex® products contributed to a 34% revenue rise, with OviTex PRS sales soaring 101%.
Despite challenges from COVID-19, the company maintained its full-year revenue guidance of $28.0 million to $30.0 million, reflecting growth of 54% to 65%. Operating expenses rose to $11.8 million, leading to a loss from operations of $7.2 million. Cash reserves stood at $53.6 million as of September 30, 2021.